Fusion molecules and uses thereof

A method of treating a subject having an FGFR3-TACC3 fusion polypeptide associated cancer, comprising:

• determining the presence of an FGFR3-TACC3 fusion polypeptide or an mRNA molecule encoding the FGFR3-TACC3 fusion polypeptide in said subject by performing an assay on a sample from the subject, wherein:
• (i) the FGFR3-TACC3 fusion polypeptide comprises encoded exons 1-17 of SEQ ID NO:
• 4 directly fused to encoded exons 8-16 of SEQ ID NO:
• 6, and a fusion junction between encoded exon 17 of SEQ ID NO:
• 4 and encoded exon 8 of SEQ ID NO:
• 6, wherein the cancer is a lung adenocarcinoma or a cervical adenocarcinoma, or
• (ii) the FGFR3-TACC3 fusion polypeptide comprises encoded exons 1-18 of SEQ ID NO:
• 4 directly fused to encoded exons 10-16 of SEQ ID NO:
• 6, and a fusion junction between encoded exon 18 of SEQ ID NO:
• 4 and encoded exon 10 of SEQ ID NO:
• 6, wherein the cancer is a uterus endometrial adenocarcinoma;
• and
• administering to the subject having the FGFR3-TACC3 fusion polypeptide or the mRNA molecule encoding the FGFR3-TACC3 fusion polypeptide an effective amount of an anti-cancer agent,
• thereby treating the cancer in the subject.